author-photo

Neil Charter

20

Papers

73

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo‐allergic and anaphylactoid reactions

2019 Pharmacology Research & Perspectives
Show All
- Source
- Cite
- Save
Citations (19)
DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (1)
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia

2019 Leukemia
Show All
- Source
- Cite
- Save
Citations (21)
Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (24)
Abstract 4874: Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

2018 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)